Program
OLN324
A development code.
Its studies are mostly in Macular Degeneration · Diabetic Retinopathy, led by Ollin Biosciences.
Furthest: phase 3, since Sep 7, 20265 company-led studies, 4 open or runningNext primary completion: Dec 15, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ollin Biosciences | 54 open or running | phase 3since Sep 7, 2026 | Mar 9, 2026 | Dec 15, 2028phase 3 · NCT07841899 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2026First study: phase 1 study in Macular DegenerationFirst studyNCT07484074 · 164 enrolled · United States, Puerto Rico
- Sep 7, 20264 phase 3 studiesPhase 3 reachedNCT07842016, NCT07841899, NCT07816315 and 1 more
Ahead
- Dec 15, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07842016
- Dec 15, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07841899
- Dec 15, 2028Primary completion: phase 3 study in Macular DegenerationNCT07816315
- Dec 15, 2028Primary completion: phase 3 study in Macular DegenerationNCT07816289
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07842016Diabetic Retinopathy | 3 | Not yet recruiting | Dec 15, 2028 | 450 |
| NCT07841899Diabetic Retinopathy | 3 | Not yet recruiting | Dec 15, 2028 | 450 |
| NCT07816315Macular Degeneration | 3 | Not yet recruiting | Dec 15, 2028 | 500 |
| NCT07816289Macular Degeneration | 3 | Not yet recruiting | Dec 15, 2028 | 400 |
| NCT07484074Macular Degeneration · United States, Puerto Rico | 1 | Completed | Oct 10, 2025 | 164 |
How it is read
Names in the registry
- “OLN324”, 5 entries
Codes read as this program: OLN324.
Conditions, from the studies’ own filings
- Macular Degeneration, 3 studies
- Diabetic Retinopathy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.